Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 5/20 | 0.54 |
| ▸ | CTSL | P07711 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3298565 | 0.88 | CTSV (0.54) | CTSVCTSLPOLBMEN1KMT2A | |
| SCHEMBL3296918 | 0.84 | HPSE (0.52) | POLBSENP8SENP7SENP6TDP1 | |
| SCHEMBL7552860 | 0.82 | MEN1 (0.53) | CTSVCTSLPOLBMEN1KMT2A | |
| SCHEMBL7761815 | 0.81 | MCL1 (0.55) | CTSVCTSLPOLBSENP8SENP7 | |
| SCHEMBL7907924 | 0.81 | CTSV (0.58) | CTSVCTSLTDP1MEN1KMT2A | |
| SCHEMBL646471 | 0.80 | MEN1 (0.54) | CTSVCTSLPOLBTDP1MEN1 | |
| SCHEMBL30061165 | 0.80 | MEN1 (0.54) | CTSVCTSLPOLBTDP1MEN1 | |
| SCHEMBL27581338 | 0.80 | MEN1 (0.51) | CTSVCTSLPOLBMEN1KMT2A | |
| SCHEMBL1647948 | 0.80 | CYP19A1 (0.64) | CTSVCTSLMEN1KMT2AMAPT | |
| SCHEMBL6665583 | 0.80 | MAOB (0.55) | CTSVCTSLMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | claimed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | claimed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | KCNQ1, KCNQ2, KCNQ5 | CTSV 4395/4885CTSL 4368/4885POLB 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.